Protox appoints Dr. Samuel Denmeade as Chief Scientific Officer

    VANCOUVER, Oct. 22 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX) today
announced that it has appointed Dr. Samuel Denmeade to the position of Chief
Scientific Officer, effective immediately.
    "Dr. Denmeade's wealth of experience as a physician and scientist with an
active clinical practice is a significant addition to the Protox team," said
Dr. Fahar Merchant, President and CEO of Protox. "As we move towards the
initiation of our Phase 2 trials for localized prostate cancer and BPH, Dr.
Denmeade's significant expertise as an investigator in several clinical
trials, as well as his substantial research in the development of PRX302 and
other targeted therapies for the treatment of cancer will be invaluable to
    Dr. Samuel Denmeade is co-inventor of PRX302, Protox's lead candidate for
the treatment of prostate cancer and BPH. He is Associate Professor at Johns
Hopkins University School of Medicine and also a member of the Chemical
Therapeutics Program within the Sidney Kimmel Comprehensive Cancer Center at
Johns Hopkins. He has an active clinical practice in genitourinary oncology
and has been the principal investigator in several clinical trials in addition
to being a co-investigator in a large number of trials conducted by the
Genitourinary Oncology Clinical Group at Johns Hopkins. Dr Denmeade has
published over 50 papers based on his laboratory research most of them focused
in the development of targeted therapies for prostate cancer. Dr. Denmeade has
been the recipient of several research awards including those from the NIH,
the Department of Defense, the Prostate Cancer Foundation and the Susan Komen
Breast Cancer Research Foundation. He graduated magna cum laude with a degree
in Biochemistry from Columbia University and earned his MD at Columbia
University College of Physicians and Surgeons. He received his residency
training at the University of Chicago before his fellowship training in
medical oncology at Johns Hopkins. Dr Denmeade is a member of the Editorial
Board of the journal, The Prostate.
    "We are very appreciative of Dr. Tom Buckley's efforts and contribution
in the successful development of Protox's pipeline," said Dr. Merchant. "While
Dr. Buckley is retiring from active laboratory research, we are pleased that
he will continue to play an important role as our scientific advisor and
consultant guiding the future growth of the PORxin platform."

    About Protox

    Protox Therapeutics is a leader in advancing novel, targeted protein
toxin therapeutics for the treatment of cancer and other proliferative
diseases. Two novel drug candidates derived from the company's INxin(TM) and
PORxin(TM) platforms, are being developed in three clinical programs. A Phase
2a clinical trial evaluating PRX321 (INxin) for the treatment of primary brain
cancer has been completed and the drug has received Fast Track Designation and
Orphan Drug Status from the US FDA. Patient enrollment has been completed in
two separate Phase 1 clinical trials evaluating PRX302 (PORxin) for the
treatment of localized prostate cancer and benign prostatic hyperplasia
(enlarged prostate).


    Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Protox'
current beliefs as well as assumptions made by and information currently
available to Protox and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Protox in its public securities filings; actual
events may differ materially from current expectations. Protox disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

For further information:

For further information: James Beesley, Director, Investor Relations,
Protox Therapeutics, (604) 484-0975,; Michael
Moore, Investor Relations, Equicom Group, (416) 815-0700 x 241,

Organization Profile

Sophiris Bio, Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890